SCR-6920 capsule Clinical Trials

1 actively recruiting trial

Also known as: PRMT5 inhibitor

Pipeline

Phase 1: 1

Top Sponsors

Jiangsu Simcere Pharmaceutical Co., Ltd.1

Indications

Non-hodgkin Lymphoma1
Solid Tumor1
Cancer1

Other1 trial

A Study to Investigate the Safety and Tolerability of SCR-6920 Capsule in Patients With Advanced Malignant Tumors

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.